| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 594.993 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 594.993. The average price that ARGX.BR shares were previous bought at was EUR 602.098. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in ARGX.BR has fallen by EUR 30,973 (USD $35,299) compared to the previous valuation of Argenx SE |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 104.54 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 104.54. The average price that GILD shares were previous bought at was USD 101.358. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 79,789 compared to the previous valuation of Guild Esports Plc |
| PODD - Insulet Corporation | HOLD | 0 @ USD 246.8 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 246.8. The average price that PODD shares were previous bought at was USD 267.167. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in PODD has fallen by USD 311,633 compared to the previous valuation of Insulet Corporation |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 49.23 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 49.23. The average price that BMY shares were previous bought at was USD 56.5981. The current market price is -13.0% lower than average price they were purchased at. The value of the holding in BMY has fallen by USD 46,060 compared to the previous valuation of Bloomsbury Publishing Plc |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 154.707 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 154.707. The average price that UCB.BR shares were previous bought at was EUR 180.614. The current market price is -14.3% lower than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 304,613 (USD $347,161) compared to the previous valuation of UCB SA |
| ILMN - Illumina Inc | HOLD | 0 @ USD 71.2 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 71.2. The average price that ILMN shares were previous bought at was USD 109.089. The current market price is -34.7% lower than average price they were purchased at. The value of the holding in ILMN has fallen by USD 314,226 compared to the previous valuation of Illumina Inc |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 482.74 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 482.74. The average price that ISRG shares were previous bought at was USD 538.802. The current market price is -10.4% lower than average price they were purchased at. The value of the holding in ISRG has increased by USD 50,962 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 148.08 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 148.08. The average price that NTRA shares were previous bought at was USD 158.953. The current market price is -6.8% lower than average price they were purchased at. The value of the holding in NTRA has fallen by USD 283,163 compared to the previous valuation of Natera Inc |
| LONN.SW - | HOLD | 0 @ CHF 657.601 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 657.601. The average price that LONN.SW shares were previous bought at was CHF 607.856. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 181,258 (USD $222,744) compared to the previous valuation of |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 95.12 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 95.12. The average price that BSX shares were previous bought at was USD 95.5935. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 25,681 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 95.12 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 95.12. The average price that BSX shares were previous bought at was USD 95.5935. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 25,681 compared to the previous valuation of MULSTRXSSXIMETFP |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 746.326 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 746.326. The average price that 207940.KS shares were previous bought at was KRW 710.518. The current market price is 5.0% higher than average price they were purchased at. The value of the holding in 207940.KS has increased by KRW 704,168 (USD $498) compared to the previous valuation of SAMSUNG BIOLOGICS LTD however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 130.98 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 130.98. The average price that ABT shares were previous bought at was USD 122.753. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in ABT has increased by USD 184,388 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 57.56 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 57.56. The average price that HOLX shares were previous bought at was USD 69.0108. The current market price is -16.6% lower than average price they were purchased at. The value of the holding in HOLX has increased by USD 220,783 compared to the previous valuation of Hologic Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 82.6 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 82.6. The average price that MDT shares were previous bought at was USD 84.6513. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in MDT has fallen by USD 18,612 compared to the previous valuation of Medtronic PLC |
| ROG.SW - | HOLD | 0 @ CHF 311.726 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 311.726. The average price that ROG.SW shares were previous bought at was CHF 298.614. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in ROG.SW has fallen by CHF 13,436 (USD $16,511) compared to the previous valuation of |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 157.47 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 157.47. The average price that JNJ shares were previous bought at was USD 153.474. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 369,973 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 172.99 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 172.99. The average price that ABBV shares were previous bought at was USD 189.714. The current market price is -8.8% lower than average price they were purchased at. The value of the holding in ABBV has increased by USD 119,129 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 102.48 | USD 0 | The current share valuation price of A based on adjusted close was USD 102.48. The average price that A shares were previous bought at was USD 128.688. The current market price is -20.4% lower than average price they were purchased at. The value of the holding in A has fallen by USD 25,436 compared to the previous valuation of Agilent Technologies Inc |
| NOVN.SW - | HOLD | 0 @ CHF 110.531 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 110.531. The average price that NOVN.SW shares were previous bought at was CHF 102.945. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in NOVN.SW has fallen by CHF 58,540 (USD $71,939) compared to the previous valuation of |
| AMGN - Amgen Inc | HOLD | 0 @ USD 277.29 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 277.29. The average price that AMGN shares were previous bought at was USD 287.303. The current market price is -3.5% lower than average price they were purchased at. The value of the holding in AMGN has fallen by USD 271,443 compared to the previous valuation of Amgen Inc |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 143.91 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 143.91. The average price that IQV shares were previous bought at was USD 185.189. The current market price is -22.3% lower than average price they were purchased at. The value of the holding in IQV has fallen by USD 319,166 compared to the previous valuation of IQVIA Holdings Inc |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 48.1 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 48.1. The average price that TECH shares were previous bought at was USD 65.5509. The current market price is -26.6% lower than average price they were purchased at. The value of the holding in TECH has fallen by USD 372,855 compared to the previous valuation of Bio-Techne Corp |
| CRL - Creightons Plc | HOLD | 0 @ USD 106.05 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 106.05. The average price that CRL shares were previous bought at was USD 166.039. The current market price is -36.1% lower than average price they were purchased at. The value of the holding in CRL has increased by USD 121,296 compared to the previous valuation of Creightons Plc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 101.38 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 101.38. The average price that NBIX shares were previous bought at was USD 115.842. The current market price is -12.5% lower than average price they were purchased at. The value of the holding in NBIX has increased by USD 145,966 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 36.19 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 36.19. The average price that EXEL shares were previous bought at was USD 34.8706. The current market price is 3.8% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 15,932 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 427.5 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 427.5. The average price that TMO shares were previous bought at was USD 500.697. The current market price is -14.6% lower than average price they were purchased at. The value of the holding in TMO has fallen by USD 244,977 compared to the previous valuation of Time Out Group plc |
| PFE - Pfizer Inc | HOLD | 0 @ USD 22.14 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 22.14. The average price that PFE shares were previous bought at was USD 25.6214. The current market price is -13.6% lower than average price they were purchased at. The value of the holding in PFE has increased by USD 54,170 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 6160.HK - BEIGENE LTD | HOLD | 0 @ HKD 17.9935 | HKD 0 | The current share valuation price of 6160.HK based on adjusted close was HKD 17.9935. The average price that 6160.HK shares were previous bought at was HKD 16.6011. The current market price is 8.4% higher than average price they were purchased at. The value of the holding in 6160.HK has fallen by HKD 61,307 (USD $7,899) compared to the previous valuation of BEIGENE LTD |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 53.79 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 53.79. The average price that SRPT shares were previous bought at was USD 96.0203. The current market price is -44.0% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 18,433 compared to the previous valuation of Sarepta Therapeutics Inc |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 18.8687 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 18.8687. The average price that 6869.T shares were previous bought at was JPY 18.5288. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 75,832 (USD $534) compared to the previous valuation of Sysmex Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 186.83 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 186.83. The average price that DHR shares were previous bought at was USD 210.496. The current market price is -11.2% lower than average price they were purchased at. The value of the holding in DHR has fallen by USD 224,048 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 186.83 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 186.83. The average price that DHR shares were previous bought at was USD 210.496. The current market price is -11.2% lower than average price they were purchased at. The value of the holding in DHR has fallen by USD 224,048 compared to the previous valuation of Danaher Corporation |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 17.6866 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 17.6866. The average price that GSK.L shares were previous bought at was GBP 17.3578. The current market price is 1.9% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 109,983 (USD $145,551) compared to the previous valuation of GlaxoSmithKline PLC |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 112.196 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 112.196. The average price that 068270.KS shares were previous bought at was KRW 126.511. The current market price is -11.3% lower than average price they were purchased at. The value of the holding in 068270.KS has increased by KRW 75,050 (USD $53) compared to the previous valuation of CELLTRION INC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 36.76 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 36.76. The average price that RVMD shares were previous bought at was USD 42.6249. The current market price is -13.8% lower than average price they were purchased at. The value of the holding in RVMD has increased by USD 120,494 compared to the previous valuation of Revolution Medicines Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 196.318 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 196.318. The average price that GMAB.CO shares were previous bought at was DKK 204.797. The current market price is -4.1% lower than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 29,705 (USD $4,534) compared to the previous valuation of |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 41.58 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 41.58. The average price that EXAS shares were previous bought at was USD 50.3477. The current market price is -17.4% lower than average price they were purchased at. The value of the holding in EXAS has fallen by USD 161,554 compared to the previous valuation of EXACT Sciences Corporation |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 27.3379 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 27.3379. The average price that 4523.T shares were previous bought at was JPY 27.4738. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 77,678 (USD $547) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 25.552 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 25.552. The average price that 7701.T shares were previous bought at was JPY 25.6814. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in 7701.T has increased by JPY 170,145 (USD $1,199) compared to the previous valuation of Shimadzu Corporation however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 71.53 | USD 0 | The current share valuation price of EW based on adjusted close was USD 71.53. The average price that EW shares were previous bought at was USD 71.7425. The current market price is -0.3% lower than average price they were purchased at. The value of the holding in EW has increased by USD 57,923 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 78 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 78. The average price that MRK shares were previous bought at was USD 89.5516. The current market price is -12.9% lower than average price they were purchased at. The value of the holding in MRK has increased by USD 177,362 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 78 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 78. The average price that MRK shares were previous bought at was USD 89.5516. The current market price is -12.9% lower than average price they were purchased at. The value of the holding in MRK has increased by USD 177,362 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 118.61 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 118.61. The average price that BIIB shares were previous bought at was USD 139.267. The current market price is -14.8% lower than average price they were purchased at. The value of the holding in BIIB has increased by USD 225,315 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 296.28 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 296.28. The average price that MEDP shares were previous bought at was USD 323.308. The current market price is -8.4% lower than average price they were purchased at. The value of the holding in MEDP has fallen by USD 6,629 compared to the previous valuation of Medpace Holdings Inc |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 238.18 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 238.18. The average price that BIO shares were previous bought at was USD 283.865. The current market price is -16.1% lower than average price they were purchased at. The value of the holding in BIO has fallen by USD 205,628 compared to the previous valuation of Bio-Rad Laboratories Inc |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 238.18 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 238.18. The average price that BIO shares were previous bought at was USD 283.865. The current market price is -16.1% lower than average price they were purchased at. The value of the holding in BIO has fallen by USD 205,628 compared to the previous valuation of Biotest Aktiengesellschaft |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 58.79 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 58.79. The average price that HALO shares were previous bought at was USD 54.767. The current market price is 7.3% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 5,206 compared to the previous valuation of Halozyme Therapeutics Inc |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 130 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 130. The average price that RGEN shares were previous bought at was USD 139.472. The current market price is -6.8% lower than average price they were purchased at. The value of the holding in RGEN has fallen by USD 143,882 compared to the previous valuation of Repligen Corporation |
| DXCM - DexCom Inc | HOLD | 0 @ USD 68.57 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 68.57. The average price that DXCM shares were previous bought at was USD 77.567. The current market price is -11.6% lower than average price they were purchased at. The value of the holding in DXCM has fallen by USD 20,782 compared to the previous valuation of DexCom Inc |
| PME.AX - | HOLD | 0 @ AUD 131.905 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 131.905. The average price that PME.AX shares were previous bought at was AUD 150.683. The current market price is -12.5% lower than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 122,934 (USD $78,346) compared to the previous valuation of however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ZEAL.CO - | HOLD | 0 @ DKK 64.5274 | DKK 0 | The current share valuation price of ZEAL.CO based on adjusted close was DKK 64.5274. The average price that ZEAL.CO shares were previous bought at was DKK 93.4172. The current market price is -30.9% lower than average price they were purchased at. The value of the holding in ZEAL.CO has fallen by DKK 12,942 (USD $1,975) compared to the previous valuation of |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 237.225 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 237.225. The average price that SRT3.DE shares were previous bought at was EUR 223.437. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 210,690 (USD $240,119) compared to the previous valuation of Sartorius AG |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 101.32 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 101.32. The average price that LNTH shares were previous bought at was USD 88.5907. The current market price is 14.4% higher than average price they were purchased at. The value of the holding in LNTH has increased by USD 71,980 compared to the previous valuation of Lantheus Holdings Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 67.36 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 67.36. The average price that MMS shares were previous bought at was USD 69.2901. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in MMS has fallen by USD 1,603 compared to the previous valuation of LYXETFETUSITETFP |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 28.4 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 28.4. The average price that IONS shares were previous bought at was USD 31.7308. The current market price is -10.5% lower than average price they were purchased at. The value of the holding in IONS has increased by USD 9,423 compared to the previous valuation of Ionis Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 129.055 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 129.055. The average price that BIM.PA shares were previous bought at was EUR 116.002. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 357,865 (USD $407,851) compared to the previous valuation of BioMerieux |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 27 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 27. The average price that ALKS shares were previous bought at was USD 32.152. The current market price is -16.0% lower than average price they were purchased at. The value of the holding in ALKS has fallen by USD 43,843 compared to the previous valuation of Alkermes Plc |
| SFZN.SW - | HOLD | 0 @ CHF 1084.21 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 1084.21. The average price that SFZN.SW shares were previous bought at was CHF 1088.75. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in SFZN.SW has fallen by CHF 11,501 (USD $14,133) compared to the previous valuation of |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 38.32 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 38.32. The average price that TGTX shares were previous bought at was USD 32.7101. The current market price is 17.2% higher than average price they were purchased at. The value of the holding in TGTX has increased by USD 19,778 compared to the previous valuation of TG Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 102.949 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 102.949. The average price that IPN.PA shares were previous bought at was EUR 113.133. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 236,774 (USD $269,846) compared to the previous valuation of Ipsen SA |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 15.1702 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 15.1702. The average price that 7747.T shares were previous bought at was JPY 16.624. The current market price is -8.7% lower than average price they were purchased at. The value of the holding in 7747.T has fallen by JPY 35,906 (USD $253) compared to the previous valuation of Asahi Intecc Co., Ltd. |
| 9926.HK - AKESO INC | HOLD | 0 @ HKD 10.6841 | HKD 0 | The current share valuation price of 9926.HK based on adjusted close was HKD 10.6841. The average price that 9926.HK shares were previous bought at was HKD 8.04218. The current market price is 32.9% higher than average price they were purchased at. The value of the holding in 9926.HK has fallen by HKD 54,556 (USD $7,029) compared to the previous valuation of AKESO INC |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 12.74 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 12.74. The average price that DNLI shares were previous bought at was USD 16.6814. The current market price is -23.6% lower than average price they were purchased at. The value of the holding in DNLI has increased by USD 31,593 compared to the previous valuation of Denali Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 104.46 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 104.46. The average price that AXSM shares were previous bought at was USD 107.527. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in AXSM has fallen by USD 486 compared to the previous valuation of Axsome Therapeutics Inc |
| CRVL - CorVel Corp | HOLD | 0 @ USD 115.09 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 115.09. The average price that CRVL shares were previous bought at was USD 112.298. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in CRVL has fallen by USD 79,385 compared to the previous valuation of CorVel Corp |
| GH - Guardant Health Inc | HOLD | 0 @ USD 44.97 | USD 0 | The current share valuation price of GH based on adjusted close was USD 44.97. The average price that GH shares were previous bought at was USD 38.4582. The current market price is 16.9% higher than average price they were purchased at. The value of the holding in GH has fallen by USD 33,444 compared to the previous valuation of Guardant Health Inc |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 33.87 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 33.87. The average price that BBIO shares were previous bought at was USD 31.1475. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in BBIO has increased by USD 3,696 compared to the previous valuation of BridgeBio Pharma Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 61.74 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 61.74. The average price that RYTM shares were previous bought at was USD 55.8525. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 28,397 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 47.39 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 47.39. The average price that PTCT shares were previous bought at was USD 46.999. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 97,143 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 24.715 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 24.715. The average price that MRNA shares were previous bought at was USD 33.4053. The current market price is -26.0% lower than average price they were purchased at. The value of the holding in MRNA has fallen by USD 49,022 compared to the previous valuation of Moderna Inc |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 62.02 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 62.02. The average price that ACLX shares were previous bought at was USD 65.7788. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in ACLX has increased by USD 58,837 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 4.39 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 4.39. The average price that NEOG shares were previous bought at was USD 11.2094. The current market price is -60.8% lower than average price they were purchased at. The value of the holding in NEOG has fallen by USD 59,572 compared to the previous valuation of Neogen Corporation |
| TECN.SW - | HOLD | 0 @ CHF 173.181 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 173.181. The average price that TECN.SW shares were previous bought at was CHF 203.143. The current market price is -14.7% lower than average price they were purchased at. The value of the holding in TECN.SW has fallen by CHF 55,541 (USD $68,253) compared to the previous valuation of |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 35.58 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 35.58. The average price that LIVN shares were previous bought at was USD 39.9884. The current market price is -11.0% lower than average price they were purchased at. The value of the holding in LIVN has increased by USD 36,173 compared to the previous valuation of LivaNova PLC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 31.14 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 31.14. The average price that VCYT shares were previous bought at was USD 39.5209. The current market price is -21.2% lower than average price they were purchased at. The value of the holding in VCYT has fallen by USD 36,717 compared to the previous valuation of Veracyte Inc |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 22.52 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 22.52. The average price that CPRX shares were previous bought at was USD 21.9579. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in CPRX has increased by USD 50,604 compared to the previous valuation of Catalyst Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 43.055 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 43.055. The average price that MRUS shares were previous bought at was USD 46.0686. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in MRUS has increased by USD 77,990 compared to the previous valuation of Merus BV however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BANB.SW - | HOLD | 0 @ CHF 57.7352 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 57.7352. The average price that BANB.SW shares were previous bought at was CHF 64.0319. The current market price is -9.8% lower than average price they were purchased at. The value of the holding in BANB.SW has fallen by CHF 40,661 (USD $49,967) compared to the previous valuation of |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 36.8 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 36.8. The average price that TWST shares were previous bought at was USD 46.6084. The current market price is -21.0% lower than average price they were purchased at. The value of the holding in TWST has fallen by USD 117,726 compared to the previous valuation of Twist Bioscience Corp |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 17.08 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 17.08. The average price that IDYA shares were previous bought at was USD 23.3136. The current market price is -26.7% lower than average price they were purchased at. The value of the holding in IDYA has increased by USD 86,382 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 23.052 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 23.052. The average price that BAVA.CO shares were previous bought at was DKK 23.6964. The current market price is -2.7% lower than average price they were purchased at. The value of the holding in BAVA.CO has fallen by DKK 6,495 (USD $991) compared to the previous valuation of |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 73.2936 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 73.2936. The average price that 326030.KS shares were previous bought at was KRW 73.2275. The current market price is 0.1% higher than average price they were purchased at. The value of the holding in 326030.KS has increased by KRW 50,686 (USD $36) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 3.06 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 3.06. The average price that IOVA shares were previous bought at was USD 3.48344. The current market price is -12.2% lower than average price they were purchased at. The value of the holding in IOVA has fallen by USD 3,047 compared to the previous valuation of Iovance Biotherapeutics Inc |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.27 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.27. The average price that GERN shares were previous bought at was USD 3.04509. The current market price is -58.3% lower than average price they were purchased at. The value of the holding in GERN has increased by USD 21,131 compared to the previous valuation of Geron Corporation however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 14.73 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 14.73. The average price that ACAD shares were previous bought at was USD 16.6937. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in ACAD has increased by USD 25,694 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 104.97 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 104.97. The average price that LGND shares were previous bought at was USD 106.995. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in LGND has increased by USD 8,113 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 30.76 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 30.76. The average price that SUPN shares were previous bought at was USD 36.111. The current market price is -14.8% lower than average price they were purchased at. The value of the holding in SUPN has increased by USD 3,554 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 25.17 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 25.17. The average price that QDEL shares were previous bought at was USD 37.1249. The current market price is -32.2% lower than average price they were purchased at. The value of the holding in QDEL has fallen by USD 6,661 compared to the previous valuation of Quidel Corporation |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 16.86 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 16.86. The average price that TNDM shares were previous bought at was USD 22.7072. The current market price is -25.8% lower than average price they were purchased at. The value of the holding in TNDM has fallen by USD 34,460 compared to the previous valuation of Tandem Diabetes Care Inc |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 17 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 17. The average price that BEAM shares were previous bought at was USD 28.1904. The current market price is -39.7% lower than average price they were purchased at. The value of the holding in BEAM has increased by USD 34,518 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 5.29 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 5.29. The average price that FTRE shares were previous bought at was USD 18.43. The current market price is -71.3% lower than average price they were purchased at. The value of the holding in FTRE has increased by USD 30,779 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 31.2052 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 31.2052. The average price that 6951.T shares were previous bought at was JPY 34.9247. The current market price is -10.7% lower than average price they were purchased at. The value of the holding in 6951.T has increased by JPY 34,558 (USD $243) compared to the previous valuation of JEOL Ltd. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.84651 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.84651. The average price that 13.HK shares were previous bought at was HKD 3.03652. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 26,974 (USD $3,475) compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 29.69 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 29.69. The average price that JANX shares were previous bought at was USD 46.4376. The current market price is -36.1% lower than average price they were purchased at. The value of the holding in JANX has increased by USD 47,963 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 15.58 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 15.58. The average price that NVCR shares were previous bought at was USD 25.4848. The current market price is -38.9% lower than average price they were purchased at. The value of the holding in NVCR has fallen by USD 32,835 compared to the previous valuation of Novocure Ltd |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 32.01 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 32.01. The average price that ATRC shares were previous bought at was USD 34.1731. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in ATRC has fallen by USD 4,394 compared to the previous valuation of AtriCure Inc |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 10.31 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 10.31. The average price that DVAX shares were previous bought at was USD 13.4762. The current market price is -23.5% lower than average price they were purchased at. The value of the holding in DVAX has fallen by USD 57,017 compared to the previous valuation of Dynavax Technologies Corporation |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 31.38 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 31.38. The average price that ASTH shares were previous bought at was USD 38.1091. The current market price is -17.7% lower than average price they were purchased at. The value of the holding in ASTH has fallen by USD 66,196 compared to the previous valuation of Astrana Health Inc |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 15.83 | USD 0 | The current share valuation price of IART based on adjusted close was USD 15.83. The average price that IART shares were previous bought at was USD 22.7476. The current market price is -30.4% lower than average price they were purchased at. The value of the holding in IART has increased by USD 7,098 compared to the previous valuation of Integra LifeSciences Holdings however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 8.6 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 8.6. The average price that ARVN shares were previous bought at was USD 18.8347. The current market price is -54.3% lower than average price they were purchased at. The value of the holding in ARVN has increased by USD 78,676 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.4 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.4. The average price that BCRX shares were previous bought at was USD 7.57922. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 48,733 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 7.51 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 7.51. The average price that TXG shares were previous bought at was USD 13.5822. The current market price is -44.7% lower than average price they were purchased at. The value of the holding in TXG has fallen by USD 70,395 compared to the previous valuation of 10X Genomics Inc |
| TXG - Terex Corporation | HOLD | 0 @ USD 7.51 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 7.51. The average price that TXG shares were previous bought at was USD 13.5822. The current market price is -44.7% lower than average price they were purchased at. The value of the holding in TXG has fallen by USD 70,395 compared to the previous valuation of Terex Corporation |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 13.4545 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 13.4545. The average price that 4887.T shares were previous bought at was JPY 13.6144. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in 4887.T has fallen by JPY 8,588 (USD $61) compared to the previous valuation of Sawai Group Holdings Co., Ltd. |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 8.96 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 8.96. The average price that EVH shares were previous bought at was USD 10.8273. The current market price is -17.2% lower than average price they were purchased at. The value of the holding in EVH has fallen by USD 37,748 compared to the previous valuation of Evolent Health Inc |
| 087010.KQ - Peptron, Inc. | HOLD | 0 @ KRW 114.31 | KRW 0 | The current share valuation price of 087010.KQ based on adjusted close was KRW 114.31. The average price that 087010.KQ shares were previous bought at was KRW 72.1254. The current market price is 58.5% higher than average price they were purchased at. The value of the holding in 087010.KQ has increased by KRW 177,452 (USD $125) compared to the previous valuation of Peptron, Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 6.70445 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 6.70445. The average price that NEU.AX shares were previous bought at was AUD 6.08057. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in NEU.AX has increased by AUD 37,318 (USD $23,783) compared to the previous valuation of however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 7.64 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 7.64. The average price that MYGN shares were previous bought at was USD 9.16323. The current market price is -16.6% lower than average price they were purchased at. The value of the holding in MYGN has fallen by USD 32,415 compared to the previous valuation of Myriad Genetics Inc |
| XNCR - Xencor Inc | HOLD | 0 @ USD 9.7 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 9.7. The average price that XNCR shares were previous bought at was USD 22.4443. The current market price is -56.8% lower than average price they were purchased at. The value of the holding in XNCR has increased by USD 14,387 compared to the previous valuation of Xencor Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.6332 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.6332. The average price that 3933.HK shares were previous bought at was HKD 1.64287. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in 3933.HK has fallen by HKD 20,277 (USD $2,612) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 28.46 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 28.46. The average price that HRMY shares were previous bought at was USD 36.675. The current market price is -22.4% lower than average price they were purchased at. The value of the holding in HRMY has increased by USD 26,150 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 25.75 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 25.75. The average price that SDGR shares were previous bought at was USD 23.9891. The current market price is 7.3% higher than average price they were purchased at. The value of the holding in SDGR has increased by USD 41,191 compared to the previous valuation of Schrodinger Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 5.5 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 5.5. The average price that RXRX shares were previous bought at was USD 7.53655. The current market price is -27.0% lower than average price they were purchased at. The value of the holding in RXRX has increased by USD 40,617 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 7.25978 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 7.25978. The average price that EVT.DE shares were previous bought at was EUR 6.46758. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in EVT.DE has increased by EUR 125,725 (USD $143,286) compared to the previous valuation of Evotec SE however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| CDNA - Caredx Inc | HOLD | 0 @ USD 17.62 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 17.62. The average price that CDNA shares were previous bought at was USD 23.6923. The current market price is -25.6% lower than average price they were purchased at. The value of the holding in CDNA has fallen by USD 38,356 compared to the previous valuation of Caredx Inc |
| CHEMM.CO - | HOLD | 0 @ DKK 72.8727 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 72.8727. The average price that CHEMM.CO shares were previous bought at was DKK 67.8797. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in CHEMM.CO has fallen by DKK 4,571 (USD $698) compared to the previous valuation of |
| CERT - Certara Inc | HOLD | 0 @ USD 14.15 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 14.15. The average price that CERT shares were previous bought at was USD 10.5217. The current market price is 34.5% higher than average price they were purchased at. The value of the holding in CERT has increased by USD 95,456 compared to the previous valuation of Certara Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 7.75 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 7.75. The average price that AUPH shares were previous bought at was USD 7.94003. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in AUPH has increased by USD 13,990 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 85.072 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 85.072. The average price that PHM.MC shares were previous bought at was EUR 85.7349. The current market price is -0.8% lower than average price they were purchased at. The value of the holding in PHM.MC has fallen by EUR 15,514 (USD $17,681) compared to the previous valuation of Pharma Mar SA |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.56023 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.56023. The average price that ONT.L shares were previous bought at was GBP 1.56738. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in ONT.L has increased by GBP 1,123 (USD $1,486) compared to the previous valuation of Oxford Nanopore Technologies Ltd however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 11.53 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 11.53. The average price that ZYME shares were previous bought at was USD 14.4693. The current market price is -20.3% lower than average price they were purchased at. The value of the holding in ZYME has increased by USD 22,820 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 24.7895 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 24.7895. The average price that GLPG.AS shares were previous bought at was EUR 26.6868. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in GLPG.AS has increased by EUR 5,590 (USD $6,371) compared to the previous valuation of Galapagos NV however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.5 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.5. The average price that VIR shares were previous bought at was USD 9.62077. The current market price is -42.8% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 8,716 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.5 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.5. The average price that VIR shares were previous bought at was USD 9.62077. The current market price is -42.8% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 8,716 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| XVIVO.ST - | HOLD | 0 @ SEK 28.9711 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 28.9711. The average price that XVIVO.ST shares were previous bought at was SEK 44.0653. The current market price is -34.3% lower than average price they were purchased at. The value of the holding in XVIVO.ST has increased by SEK 11,486 (USD $1,178) compared to the previous valuation of however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 45.738 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 45.738. The average price that 298380.KQ shares were previous bought at was KRW 29.3564. The current market price is 55.8% higher than average price they were purchased at. The value of the holding in 298380.KQ has increased by KRW 63,231 (USD $45) compared to the previous valuation of ABL Bio Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6. The average price that NVAX shares were previous bought at was USD 6.74881. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in NVAX has fallen by USD 30,815 compared to the previous valuation of Novavax Inc |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6. The average price that NVAX shares were previous bought at was USD 6.74881. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in NVAX has fallen by USD 30,815 compared to the previous valuation of Hana Microelectronics Public Company Limited |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.47 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.47. The average price that IBRX shares were previous bought at was USD 2.83579. The current market price is -12.9% lower than average price they were purchased at. The value of the holding in IBRX has fallen by USD 2,565 compared to the previous valuation of Immunitybio Inc |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 3.65 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 3.65. The average price that CTKB shares were previous bought at was USD 5.97881. The current market price is -39.0% lower than average price they were purchased at. The value of the holding in CTKB has fallen by USD 3,468 compared to the previous valuation of Cytek Biosciences Inc |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 21.51 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 21.51. The average price that CSTL shares were previous bought at was USD 26.5475. The current market price is -19.0% lower than average price they were purchased at. The value of the holding in CSTL has increased by USD 8,551 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 5.49337 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 5.49337. The average price that 2162.HK shares were previous bought at was HKD 4.88626. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in 2162.HK has increased by HKD 28,835 (USD $3,715) compared to the previous valuation of KEYMED BIOSCIENCES INC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 9.2 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 9.2. The average price that PRTA shares were previous bought at was USD 14.8359. The current market price is -38.0% lower than average price they were purchased at. The value of the holding in PRTA has fallen by USD 4,143 compared to the previous valuation of Prothena Corporation plc |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 27.5908 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 27.5908. The average price that 302440.KS shares were previous bought at was KRW 33.0312. The current market price is -16.5% lower than average price they were purchased at. The value of the holding in 302440.KS has increased by KRW 19,031 (USD $13) compared to the previous valuation of SK BIOSCIENCE LTD however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 2.69 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 2.69. The average price that RLAY shares were previous bought at was USD 3.97977. The current market price is -32.4% lower than average price they were purchased at. The value of the holding in RLAY has increased by USD 14,879 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 7.33 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 7.33. The average price that ADPT shares were previous bought at was USD 5.54285. The current market price is 32.2% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 30,918 compared to the previous valuation of Adaptive Biotechnologies Corp |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 17.0901 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 17.0901. The average price that 096530.KQ shares were previous bought at was KRW 16.2911. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in 096530.KQ has increased by KRW 5,261 (USD $4) compared to the previous valuation of Seegene, Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 7.88001 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 7.88001. The average price that RCUS shares were previous bought at was USD 10.8479. The current market price is -27.4% lower than average price they were purchased at. The value of the holding in RCUS has increased by USD 1,601 compared to the previous valuation of Arcus Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 37.7039 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 37.7039. The average price that 328130.KQ shares were previous bought at was KRW 40.2966. The current market price is -6.4% lower than average price they were purchased at. The value of the holding in 328130.KQ has increased by KRW 28,631 (USD $20) compared to the previous valuation of Lunit Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 53.6312 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 53.6312. The average price that 237690.KQ shares were previous bought at was KRW 47.3972. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in 237690.KQ has increased by KRW 4,937 (USD $3) compared to the previous valuation of ST Pharm Co.,Ltd. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 2.42 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 2.42. The average price that ABCL shares were previous bought at was USD 3.29677. The current market price is -26.6% lower than average price they were purchased at. The value of the holding in ABCL has increased by USD 8,359 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 1.77 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 1.77. The average price that MRVI shares were previous bought at was USD 3.8488. The current market price is -54.0% lower than average price they were purchased at. The value of the holding in MRVI has increased by USD 7,090 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.17 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.17. The average price that PACB shares were previous bought at was USD 1.74193. The current market price is -32.8% lower than average price they were purchased at. The value of the holding in PACB has fallen by USD 10,301 compared to the previous valuation of Pacific Biosciences of California |
| AXGN - Axogen Inc | HOLD | 0 @ USD 15.57 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 15.57. The average price that AXGN shares were previous bought at was USD 18.855. The current market price is -17.4% lower than average price they were purchased at. The value of the holding in AXGN has fallen by USD 530 compared to the previous valuation of Axogen Inc |
| 6550.TW - Polaris Group | HOLD | 0 @ TWD 1.23755 | TWD 0 | The current share valuation price of 6550.TW based on adjusted close was TWD 1.23755. The average price that 6550.TW shares were previous bought at was TWD 1.5347. The current market price is -19.4% lower than average price they were purchased at. The value of the holding in 6550.TW has increased by TWD 51,206 (USD $1,581) compared to the previous valuation of Polaris Group however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| DYVOX.ST - | HOLD | 0 @ SEK 5.7911 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 5.7911. The average price that DYVOX.ST shares were previous bought at was SEK 5.73853. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in DYVOX.ST has increased by SEK 4,469 (USD $458) compared to the previous valuation of however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| QTRX - Quanterix Corp | HOLD | 0 @ USD 5.14999 | USD 0 | The current share valuation price of QTRX based on adjusted close was USD 5.14999. The average price that QTRX shares were previous bought at was USD 7.8151. The current market price is -34.1% lower than average price they were purchased at. The value of the holding in QTRX has fallen by USD 449 compared to the previous valuation of Quanterix Corp |
| RO.SW - | HOLD | 0 @ CHF 329.045 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 329.045. The average price that RO.SW shares were previous bought at was CHF 369.075. The current market price is -10.8% lower than average price they were purchased at. The value of the holding in RO.SW has fallen by CHF 1,336 (USD $1,642) compared to the previous valuation of |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 10.2658 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 10.2658. The average price that 7575.T shares were previous bought at was JPY 10.5211. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in 7575.T has fallen by JPY 572 (USD $4) compared to the previous valuation of Japan Lifeline Co., Ltd. |
| YMAB - Y mAbs Therapeutics | HOLD | 0 @ USD 4.69 | USD 0 | The current share valuation price of YMAB based on adjusted close was USD 4.69. The average price that YMAB shares were previous bought at was USD 6.155. The current market price is -23.8% lower than average price they were purchased at. The value of the holding in YMAB has increased by USD 7,311 compared to the previous valuation of Y mAbs Therapeutics however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 0.79567 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 0.79567. The average price that PHARM.AS shares were previous bought at was EUR 0.792957. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in PHARM.AS has fallen by EUR 8,333 (USD $9,497) compared to the previous valuation of Pharming Group NV |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 32.69 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 32.69. The average price that SLP shares were previous bought at was USD 26.9197. The current market price is 21.4% higher than average price they were purchased at. The value of the holding in SLP has increased by USD 9,765 compared to the previous valuation of Sylvania Platinum Limited however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ALEC - Alector Inc | HOLD | 0 @ USD 0.920097 | USD 0 | The current share valuation price of ALEC based on adjusted close was USD 0.920097. The average price that ALEC shares were previous bought at was USD 1.7975. The current market price is -48.8% lower than average price they were purchased at. The value of the holding in ALEC has fallen by USD 6,033 compared to the previous valuation of Alector Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 10.53 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 10.53. The average price that ARCT shares were previous bought at was USD 17.1025. The current market price is -38.4% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 6,601 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 4.28908 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 4.28908. The average price that 9995.HK shares were previous bought at was HKD 2.06854. The current market price is 107.3% higher than average price they were purchased at. The value of the holding in 9995.HK has fallen by HKD 45,200 (USD $5,823) compared to the previous valuation of REMEGEN LTD H |
| COP.DE - CompuGroup Medical SE & Co KgaA | HOLD | 0 @ EUR 25.13 | EUR 0 | The current share valuation price of COP.DE based on adjusted close was EUR 25.13. The average price that COP.DE shares were previous bought at was EUR 23.6617. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in COP.DE has fallen by EUR 877 (USD $999) compared to the previous valuation of CompuGroup Medical SE & Co KgaA |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.4901 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.4901. The average price that 4549.T shares were previous bought at was JPY 13.6107. The current market price is 13.8% higher than average price they were purchased at. The value of the holding in 4549.T has increased by JPY 6,823 (USD $48) compared to the previous valuation of Eiken Chemical Co., Ltd. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 5.94001 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 5.94001. The average price that RGNX shares were previous bought at was USD 7.30433. The current market price is -18.7% lower than average price they were purchased at. The value of the holding in RGNX has fallen by USD 11,060 compared to the previous valuation of Regenxbio Inc |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 7.69 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 7.69. The average price that STOK shares were previous bought at was USD 9.13562. The current market price is -15.8% lower than average price they were purchased at. The value of the holding in STOK has increased by USD 4,596 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.45 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.45. The average price that ALLO shares were previous bought at was USD 2.4463. The current market price is -40.7% lower than average price they were purchased at. The value of the holding in ALLO has increased by USD 8,389 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 20.55 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 20.55. The average price that ANAB shares were previous bought at was USD 19.0376. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 32,987 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.5618 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.5618. The average price that 4974.T shares were previous bought at was JPY 5.91999. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in 4974.T has increased by JPY 6,043 (USD $43) compared to the previous valuation of Takara Bio Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 3.06 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 3.06. The average price that FDMT shares were previous bought at was USD 4.7125. The current market price is -35.1% lower than average price they were purchased at. The value of the holding in FDMT has increased by USD 8,252 compared to the previous valuation of 4D Molecular Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ITOS - Iteos Therapeutics Inc | HOLD | 0 @ USD 6.51001 | USD 0 | The current share valuation price of ITOS based on adjusted close was USD 6.51001. The average price that ITOS shares were previous bought at was USD 7.355. The current market price is -11.5% lower than average price they were purchased at. The value of the holding in ITOS has increased by USD 13,318 compared to the previous valuation of Iteos Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| OSUR - OraSure Technologies Inc | HOLD | 0 @ USD 2.99 | USD 0 | The current share valuation price of OSUR based on adjusted close was USD 2.99. The average price that OSUR shares were previous bought at was USD 3.96007. The current market price is -24.5% lower than average price they were purchased at. The value of the holding in OSUR has increased by USD 6,829 compared to the previous valuation of OraSure Technologies Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 4.33001 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 4.33001. The average price that VNDA shares were previous bought at was USD 4.505. The current market price is -3.9% lower than average price they were purchased at. The value of the holding in VNDA has fallen by USD 2,972 compared to the previous valuation of Vanda Pharmaceuticals Inc |
| SAGE - Sage Therapeutic | HOLD | 0 @ USD 7.43 | USD 0 | The current share valuation price of SAGE based on adjusted close was USD 7.43. The average price that SAGE shares were previous bought at was USD 7.15. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in SAGE has increased by USD 4,161 compared to the previous valuation of Sage Therapeutic however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 137310.KS - SD BIOSENSOR INC | HOLD | 0 @ KRW 6.32862 | KRW 0 | The current share valuation price of 137310.KS based on adjusted close was KRW 6.32862. The average price that 137310.KS shares were previous bought at was KRW 7.48114. The current market price is -15.4% lower than average price they were purchased at. The value of the holding in 137310.KS has increased by KRW 7,580 (USD $5) compared to the previous valuation of SD BIOSENSOR INC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 9.67001 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 9.67001. The average price that URGN shares were previous bought at was USD 9.99368. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in URGN has fallen by USD 27,136 compared to the previous valuation of UroGen Pharma Ltd |
| 019170.KS - SHINPOONG PHARMACEUTICAL LTD | HOLD | 0 @ KRW 5.32085 | KRW 0 | The current share valuation price of 019170.KS based on adjusted close was KRW 5.32085. The average price that 019170.KS shares were previous bought at was KRW 6.23277. The current market price is -14.6% lower than average price they were purchased at. The value of the holding in 019170.KS has fallen by KRW 7,156 (USD $5) compared to the previous valuation of SHINPOONG PHARMACEUTICAL LTD |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 1.83413 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 1.83413. The average price that 1877.HK shares were previous bought at was HKD 1.68467. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in 1877.HK has fallen by HKD 2,170 (USD $280) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H |
| MRSN - Mersana Therapeutics Inc | HOLD | 0 @ USD 0.354699 | USD 0 | The current share valuation price of MRSN based on adjusted close was USD 0.354699. The average price that MRSN shares were previous bought at was USD 0.556099. The current market price is -36.2% lower than average price they were purchased at. The value of the holding in MRSN has increased by USD 3,127 compared to the previous valuation of Mersana Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ATAI - ATAI Life Sciences BV | HOLD | 0 @ USD 1.47 | USD 0 | The current share valuation price of ATAI based on adjusted close was USD 1.47. The average price that ATAI shares were previous bought at was USD 1.9916. The current market price is -26.2% lower than average price they were purchased at. The value of the holding in ATAI has increased by USD 10,707 compared to the previous valuation of ATAI Life Sciences BV however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| FATE - Fate Therapeutics Inc | HOLD | 0 @ USD 1.11 | USD 0 | The current share valuation price of FATE based on adjusted close was USD 1.11. The average price that FATE shares were previous bought at was USD 1.54486. The current market price is -28.1% lower than average price they were purchased at. The value of the holding in FATE has increased by USD 7,761 compared to the previous valuation of Fate Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MGNX - MacroGenics Inc | HOLD | 0 @ USD 1.26001 | USD 0 | The current share valuation price of MGNX based on adjusted close was USD 1.26001. The average price that MGNX shares were previous bought at was USD 2.805. The current market price is -55.1% lower than average price they were purchased at. The value of the holding in MGNX has increased by USD 5,938 compared to the previous valuation of MacroGenics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 099190.KQ - i-SENS, Inc. | HOLD | 0 @ KRW 10.691 | KRW 0 | The current share valuation price of 099190.KQ based on adjusted close was KRW 10.691. The average price that 099190.KQ shares were previous bought at was KRW 11.5539. The current market price is -7.5% lower than average price they were purchased at. The value of the holding in 099190.KQ has increased by KRW 5,269 (USD $4) compared to the previous valuation of i-SENS, Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| STRO - Sutro Biopharma | HOLD | 0 @ USD 0.524605 | USD 0 | The current share valuation price of STRO based on adjusted close was USD 0.524605. The average price that STRO shares were previous bought at was USD 1.815. The current market price is -71.1% lower than average price they were purchased at. The value of the holding in STRO has fallen by USD 1,127 compared to the previous valuation of Sutro Biopharma |
| 215600.KQ - SillaJen, Inc. | HOLD | 0 @ KRW 1.63149 | KRW 0 | The current share valuation price of 215600.KQ based on adjusted close was KRW 1.63149. The average price that 215600.KQ shares were previous bought at was KRW 1.74108. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in 215600.KQ has increased by KRW 4,819 (USD $3) compared to the previous valuation of SillaJen, Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 3.44601 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 3.44601. The average price that VLA.PA shares were previous bought at was EUR 3.80182. The current market price is -9.4% lower than average price they were purchased at. The value of the holding in VLA.PA has increased by EUR 3,436 (USD $3,916) compared to the previous valuation of Valneva SE however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 0.433602 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 0.433602. The average price that LYEL shares were previous bought at was USD 0.626154. The current market price is -30.8% lower than average price they were purchased at. The value of the holding in LYEL has fallen by USD 1,260 compared to the previous valuation of Lyell Immunopharma Inc |
| QURE - Uniqure NV | HOLD | 0 @ USD 13 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 13. The average price that QURE shares were previous bought at was USD 6.07363. The current market price is 114.0% higher than average price they were purchased at. The value of the holding in QURE has increased by USD 207,149 compared to the previous valuation of Uniqure NV however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 6523.T - PHC Holdings Corporation | HOLD | 0 @ JPY 6.59541 | JPY 0 | The current share valuation price of 6523.T based on adjusted close was JPY 6.59541. The average price that 6523.T shares were previous bought at was JPY 6.00966. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in 6523.T has fallen by JPY 372 (USD $3) compared to the previous valuation of PHC Holdings Corporation |
| CRBU - Caribou Biosciences Inc | HOLD | 0 @ USD 0.735003 | USD 0 | The current share valuation price of CRBU based on adjusted close was USD 0.735003. The average price that CRBU shares were previous bought at was USD 1.37997. The current market price is -46.7% lower than average price they were purchased at. The value of the holding in CRBU has increased by USD 165 compared to the previous valuation of Caribou Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| IDIA.SW - | HOLD | 0 @ CHF 1.39033 | CHF 0 | The current share valuation price of IDIA.SW based on adjusted close was CHF 1.39033. The average price that IDIA.SW shares were previous bought at was CHF 0.93285. The current market price is 49.0% higher than average price they were purchased at. The value of the holding in IDIA.SW has increased by CHF 1,903 (USD $2,339) compared to the previous valuation of however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 0.963496 | KRW 0 | |
| AGEN - Agenus Inc | HOLD | 0 @ USD 2.07998 | USD 0 | The current share valuation price of AGEN based on adjusted close was USD 2.07998. The average price that AGEN shares were previous bought at was USD 3.3925. The current market price is -38.7% lower than average price they were purchased at. The value of the holding in AGEN has increased by USD 9,715 compared to the previous valuation of Agenus Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SECT-B.ST - | HOLD | 0 @ SEK 28.4941 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 28.4941. The average price that SECT-B.ST shares were previous bought at was SEK 23.4461. The current market price is 21.5% higher than average price they were purchased at. The value of the holding in SECT-B.ST has increased by SEK 82,102 (USD $8,419) compared to the previous valuation of however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| EKTA-B.ST - | HOLD | 0 @ SEK 4.93566 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 4.93566. The average price that EKTA-B.ST shares were previous bought at was SEK 6.04222. The current market price is -18.3% lower than average price they were purchased at. The value of the holding in EKTA-B.ST has fallen by SEK 9,055 (USD $929) compared to the previous valuation of |
| HLUN-B.CO - | HOLD | 0 @ DKK 4.34135 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 4.34135. The average price that HLUN-B.CO shares were previous bought at was DKK 5.79579. The current market price is -25.1% lower than average price they were purchased at. The value of the holding in HLUN-B.CO has fallen by DKK 4,191 (USD $640) compared to the previous valuation of |
| BIOA-B.ST - | HOLD | 0 @ SEK 17.4304 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 17.4304. The average price that BIOA-B.ST shares were previous bought at was SEK 22.2632. The current market price is -21.7% lower than average price they were purchased at. The value of the holding in BIOA-B.ST has increased by SEK 22,606 (USD $2,318) compared to the previous valuation of however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 40.8391 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 40.8391. The average price that QIA.DE shares were previous bought at was EUR 39.5309. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 262,351 (USD $298,996) compared to the previous valuation of QIAGEN NV |
| DIA.MI - DiaSorin SpA | SELL | -661 @ EUR 111.144 | EUR -73,466 | The ETF sold 661 shares of DIA.MI on 2025-04-17. The shares were previously bought for an average price of EUR 63.4401. The DiaSorin SpA shares were sold for 75.2% higher than average price of previous purchases. This sale made a profit of EUR 31,532 (USD $35,937) The average price that the ETF previously sold DIA.MI share for is EUR 108.269 so the ETF has sold 661 shares on 2025-04-17 at a higher price than the previous selling average. |